Japan GMP Ordinance (MHLW Ministerial Ordinance No. 179, 2004) Audit-Readiness Rubric — Regscribe v0
(Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Drugs and Quasi-drugs)
Scope boundary — read this before scoring anything. Japan splits what the EU folds into a single GMP framework and what the US folds into 21 CFR 210/211 across three separate ordinances, all issued by MHLW on the same day (24 December 2004) and all made under the same parent statute:
- GMP Ordinance — MHLW Ministerial Ordinance No. 179, 2004 ("Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Drugs and Quasi-drugs") — this document. Governs manufacturing-site control: buildings/facilities, manufacturing control, quality control (in-process/release testing, reserve samples), validation, change control, deviation control, self-inspection, training, and document/record control at the manufacturing site.
- GQP Ordinance — MHLW Ministerial Ordinance No. 136, 2004 ("Ministerial Ordinance on Standards for Quality Assurance for Drugs, Quasi-drugs, Cosmetics and Medical Devices") — governs the Marketing Authorisation Holder's (MAH) post-approval quality oversight of its manufacturers, including the MAH-side quality assurance department and the decision to release product to market. Not covered in this rubric. A Japan-market drug company needs both GMP and GQP compliance; a document-analysis tool scoring only against this GMP rubric will not catch GQP-only gaps (e.g., MAH-level oversight failures where the manufacturing site itself was compliant).
- GVP Ordinance — MHLW Ministerial Ordinance No. 135, 2004 ("Ministerial Ordinance on Standards for Post-marketing Safety Management for Drugs, Quasi-drugs, Cosmetics and Medical Devices") — governs post-marketing pharmacovigilance/safety-information management. Not covered in this rubric and not a manufacturing-quality topic at all — it is Japan's rough analogue to EU pharmacovigilance obligations, not to GMP.
Parent statute: all three ordinances are issued under Japan's Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices — universally abbreviated the PMD Act (Act No. 145, 1960, as amended). The PMD Act was known as the Pharmaceutical Affairs Law (PAL) until a 2013 amendment (in force 25 November 2014) renamed and re-scoped it to explicitly cover medical devices and regenerative-medicine products alongside drugs. The GMP Ordinance's own text (Article 1) still cites "Pharmaceutical Affairs Law (Law No. 145, 1960)" because the translation on file predates the rename — the citation is to the same Act under its current name.
PIC/S note: Japan (PMDA/MHLW) joined the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2014. Since a February 2012 MHLW notification ("Application of PIC/s GMP Guide," Compliance and Narcotics Division, Pharmaceuticals and Food Safety Bureau), Japanese GMP inspectors are instructed to use the PIC/S GMP Guide as an interpretive/inspection reference, and manufacturers may demonstrate compliance via methods equivalent-or-superior to the PIC/S Guide even where the GMP Ordinance's own text is less granular. This means the PIC/S Guide (and, by extension, the EU GMP Vol. 4 text it closely tracks) is a legitimate secondary interpretive source for Japan GMP even though it is not itself binding Japanese law. This rubric treats the GMP Ordinance articles as the citable legal requirement and notes PIC/S/EU-GMP alignment only as cross-reference commentary, never as a substitute citation.
Sources used
Regulatory text (primary, structure, article numbers, article text):
- PMDA's own official English-language tentative translation of MHLW Ministerial Ordinance No. 179, 2004 — fetched directly from
https://www.pmda.go.jp/files/000153399.pdf(linked from PMDA's English "Ministerial Ordinances" index page,pmda.go.jp/english/review-services/regulatory-info/0001.html). This is a scanned/image PDF (not a text-layer PDF), so it could not be extracted via automated WebFetch text-extraction; it was instead read page-by-page as page images (23 pages total), which succeeded cleanly and yielded the full Contents page, all 32 articles verbatim, and the Supplementary Provisions. This is the single primary source underlying every article citation and article-text paraphrase in this rubric. - The translation is explicitly labeled "Tentative translation VER. 1" with a footnote stating: "This is a tentative translation of afore-mentioned Ordinance in English which is not authentic and not formally authorised by Ministry of Health, Labour and Welfare of Japan." Treat all article wording below as substantively accurate to the official translation on file at PMDA, but not itself the authoritative Japanese legal text — standard practice for any non-Japanese-language citation of Japanese law, and the same caveat PMDA itself attaches.
- No visible revision/amendment date stamp was found on this specific PDF. Cross-referencing against secondary sources (below) indicates the ordinance has been amended at least once since 2004 (see amendment-currency gap below) — this rubric's article numbering and text should be treated as reflecting the 2004 original ordinance as in force from 1 April 2005, with amendment currency unverified.
- A second PMDA PDF (
pmda.go.jp/files/000153550.pdf, "Tentative translation as of February 20, 2012") was also fetched and read — this turned out to be a different document: a bilingual (English/Japanese) MHLW administrative notice instructing prefectural health authorities to apply the PIC/S GMP Guide as an inspection reference, with the PIC/S GMP Guide Part I (Chapters 1–2 at minimum, confirmed via page-image read) attached as a side-by-side translation table. This is a genuinely useful primary-ish source (an official MHLW notification) for the PIC/S-alignment claim above, but it is not the GMP Ordinance itself and should not be cited as such — flagged so the two PDFs are not confused with each other in future sessions. - GQP Ordinance citation (No. 136, 2004) was independently confirmed two ways: (a) it is referenced inside the GMP Ordinance's own Article 11(1)(3) text ("...Ministerial Ordinance on Standards for Quality Assurance for Drugs, Quasi-drugs, Cosmetics and Medical Devices (MHLW Ministerial Ordinance No. 136, 2004)..."), and (b) independently via WebSearch. GVP Ordinance citation (No. 135, 2004) was sourced via WebSearch only (title: "Ministerial Ordinance on Standards for Post-marketing Safety Management for Drugs, Quasi-drugs, Cosmetics and Medical Devices") — this session did not independently pull GVP's primary PMDA text to verify article numbering, since GVP is out of scope for this rubric; flagged as secondary-sourced.
- PMD Act rename (2013 amendment, in force 25 Nov 2014) confirmed via WebSearch across multiple consistent secondary sources (Jones Day legal alert, Freyr Solutions, PMDA FAQ page) — consistent across sources, treated as reliable, but no single primary-statute citation was independently pulled this session.
Enforcement / failure-pattern data:
- Kobayashi Kako Co., Ltd. (2020–2021) — a real, well-documented, directly GMP-relevant case: an oral antifungal drug (itraconazole) was found contaminated with an unauthorized sleep-inducing substance during manufacturing (at least 245 adverse-event reports, including 2 deaths from loss of consciousness while driving); a third-party investigation found the company had manufactured via unauthorized/undocumented procedures since 2005 and, per the sourced summary, had not conducted required quality tests since the late 1970s, fabricating results instead; Fukui Prefecture ordered a 116-day business suspension (9 Feb 2021 — reported as the longest ever issued to a Japanese pharmaceutical manufacturer), MHLW separately revoked marketing approvals for multiple products, and the company filed for bankruptcy (acquired by Sawai Pharmaceutical, March 2022). Sourced via a peer-reviewed article (Suzuki & Kamei, "Generic drug crisis in Japan...", PMC10230667, open-access PMC) cross-checked against contemporaneous trade-press coverage (Fierce Pharma, PHARMA JAPAN) — treated as high-confidence, directly on-point, current-era (not founding-era) GMP enforcement evidence, marked [REPRESENTATIVE] below since the specific article-level GMP Ordinance citation violated was not stated in the sources found (the case clearly implicates Articles 10/11 manufacturing-and-quality-control duties, Article 20 record integrity, and Article 15 deviation control in substance, but no MHLW enforcement notice itself was independently retrieved to confirm article-by-article attribution).
- Nichi-Iko Pharmaceutical Co., Ltd. (2021) — Japan's largest generic manufacturer at the time; same peer-reviewed source states it had been "operating with unauthorized procedures since 2009" and received a production-suspension order in March 2021. Same sourcing/confidence caveat as above — [REPRESENTATIVE].
- Systemic scale: the same source states that, as of August 2021, 743 of 15,433 tracked medications had suspended shipment and 2,400 were under-shipped, precipitating a nationwide generic-drug shortage — cited as context for why GMP non-compliance in Japan carries unusually large downstream market impact (concentrated generic-manufacturer base), not as a per-clause failure pattern.
- No official MHLW or PMDA enforcement-notice document (e.g., a formal administrative-disposition notice analogous to an FDA Warning Letter) was independently fetched this session for either case — both are sourced from peer-reviewed secondary literature and trade press, not primary regulator-issued enforcement text. This is a materially weaker sourcing tier than the FDA 210/211 rubric's warning-letter citations and should be treated accordingly.
- Explicitly excluded, with reasoning: the 2024 "Kobayashi Pharmaceutical beni-koji (red yeast rice)" scandal (widely reported, dozens of deaths investigated, WHO/international attention) was investigated this session and deliberately excluded from this rubric — the implicated products were sold in Japan as foods with function claims (a food-labeling category), not as drugs or quasi-drugs, and therefore fall outside the PMD Act / GMP Ordinance No. 179's scope entirely (Article 3 of the Ordinance limits scope to drug/quasi-drug marketing authorisation holders and their manufacturers). Flagged explicitly per this project's "never fabricate/conflate" rule — it is a real and serious case, but citing it as a "GMP violation example" in this rubric would misrepresent both the case and the regulation's scope.
- No MHLW/PMDA-published aggregate GMP inspection-deficiency dataset (i.e., nothing analogous to MHRA's published GMP Inspection Deficiency Data Trend reports used in the
gmp-gdp-rubric.mdcompanion doc) was found this session. This appears to be a genuine transparency gap on the regulator's side, not a search failure — MHLW/PMDA do not appear to publish per-clause inspection-finding frequency data in English. Flagged in Gaps below.
2021 amendment (structural currency):
- WebSearch surfaced a reference to a MHLW notification titled "Notification Concerning Partial Amendment of the Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Drugs and Quasi-drugs," dated 28 April 2021, and a separate claim that a 2021 amendment added provisions for remanufactured single-use medical devices. Neither claim was independently verified against a primary MHLW/PMDA document this session — the single-use-device claim in particular looks structurally more consistent with Japan's medical device QMS ordinance (a different ordinance, No. 169, covering devices, not drugs/quasi-drugs) than with Ordinance No. 179, and may be a search-result conflation rather than a fact about this specific ordinance. This entire amendment claim is flagged as [UNVERIFIED — flagged, not used] — nothing about it is relied upon in the article-level rows below, which are drawn only from the primary-source 2004 text actually read. See Gaps section.
Rubric legend
Each row: Requirement (plain language) → Citation → Evidence that demonstrates compliance → Common failure pattern
Failure-pattern cells are marked:
- [REPRESENTATIVE] — a real, confirmed, publicly-documented enforcement case (Kobayashi Kako, Nichi-Iko) or a well-established GMP failure mode drawn from the Ordinance's own structure/PIC/S cross-reference commentary, but not confirmed against a primary MHLW/PMDA enforcement-notice document naming the specific article violated.
- [ANALOGOUS] — a real, confirmed case that is structurally similar and instructive, but was not an enforcement action under this GMP Ordinance specifically (e.g., a food-labeling case, or a case under GQP/GVP rather than GMP) — included, where included at all, purely as illustrative context with the caveat stated inline, never as GMP Ordinance precedent.
- [UNVERIFIED — flagged, not used] — a claim (chiefly the 2021-amendment claim above) that could not be independently verified this session and is therefore not used to support any requirement row below — reserved marker, consistent with the companion GLP rubric's usage.
- No [HISTORICAL] marker is used in this document — unlike the GLP rubric's 1970s-founding-scandal citations, no verified "why this ordinance was originally written" origin-story case was found for the 2004 Japan GMP Ordinance this session (Japan's GMP framework has a longer administrative history than 2004 — the 2004 ordinance was itself a revision of a 1999 predecessor per its own preamble — but the specific originating scandal, if any, was not researched this session).
CHAPTER 1 — General Provisions
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 1 | Purpose: this Ministerial Ordinance provides the GMP standards required under the PMD Act (Article 14, Paragraph 2, Item 4, and by extension Article 19-2 Paragraph 5 for foreign/marketing-authorisation-holder cases). | GMP Ordinance, Art. 1 | N/A — reference/gating section; confirms a document is in scope for this rubric at all | N/A |
| 2 | Definitions: "Product," "Packaging and labelling material," "Lot," "Controlled unit," "Validation," "Clean area," "Aseptic area," "Cell/tissue-based drug," "Donor," "Donor animal" are all defined here and drive downstream scoring (e.g., whether a given manufacturing run constitutes a "Lot" subject to lot-based recordkeeping). | GMP Ordinance, Art. 2 | N/A — reference section | N/A |
| 3 | Scope: applies to marketing-authorisation holders (and appointed MAHs) of drugs (excluding in-vitro diagnostic reagents) or quasi-drugs, who must have their manufacturer(s) — domestic or foreign — conduct manufacturing control and quality control per Chapter 2 (drugs) or Chapter 2 as applied mutatis mutandis under Chapter 3 (quasi-drugs); also applies to export-only manufacturing under PMD Act Art. 80(1). | GMP Ordinance, Art. 3 | N/A — reference/gating section. Use to confirm the document under analysis actually concerns a drug or quasi-drug manufacturing site (not, e.g., a food/cosmetic/medical-device site, which fall under different ordinances) before scoring any other row. | N/A |
CHAPTER 2, Section 1 — General Rules (all drug manufacturing sites)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 4 | Manufacturing Department and Quality Department: the manufacturer must establish, at each manufacturing site, a manufacturing-control department and a quality-control department, both under the supervision of a designated "manufacturing manager" (drug manufacturing manager under PMD Act Art. 17(3), or the manufacturing-site-responsible person for a foreign manufacturer). The quality department must be independent of the manufacturing department. | GMP Ordinance, Art. 4(1)-(2) | Organisational chart showing the quality department's reporting line is not through the manufacturing department; manufacturing-manager appointment record | [REPRESENTATIVE] This is Japan's direct structural analogue to EU GMP Ch.1's PQS senior-management-responsibility clause and to FDA's QCU-independence requirement (21 CFR 211.22) — a quality department that reports up through manufacturing/production management, rather than independently, is the same "independence-in-name-only" finding pattern documented in the companion EU/US rubrics, and should be checked the same way here: verify the actual reporting line, not just an org-chart label. |
| 5 | Manufacturing Manager duties: supervise manufacturing-and-quality-control duties for proper/efficient conduct; verify that necessary corrective actions are promptly taken and progress is verified where a quality defect or potential quality risk exists; the manufacturer must ensure the manufacturing manager can perform these duties without hindrance. | GMP Ordinance, Art. 5(1)-(2) | Manufacturing-manager job description/authority charter; documented instance of the manager directing corrective action on an identified quality risk | [REPRESENTATIVE] A manufacturing manager whose corrective-action instructions are routinely overridden or delayed by production-schedule pressure — with no documented escalation — is the practical version of the "without hindrance" clause being violated; hard to detect from a single document, but a pattern across multiple deviation records (see Art. 15) is the tell. |
| 6 | Personnel (Responsible Persons): the manufacturer must appropriately assign "responsible persons" competent to conduct manufacturing-and-quality-control duties according to the site's organisation/size/duty type, in sufficient numbers, with the scope of responsibilities and supervision structure documented. | GMP Ordinance, Art. 6(1)-(4) | Responsible-person assignment records mapped to specific duties; documented org structure showing supervision lines | [REPRESENTATIVE] Understaffing relative to product-line complexity is a documented real-world root cause in the Kobayashi Kako case — reporting indicates roughly 800 employees were responsible for some 500 product types, a mismatch later cited as a contributing systemic factor in that company's quality failures (see Sources). |
| 7 | Seihin Hyojun Sho (Product Standard Book): for each product, the manufacturer must establish and maintain a Seihin Hyojun Sho — approved by the quality department — describing marketing-approval items, applicable standards under PMD Act Art. 42(1) and related quality-relevant laws/orders, the manufacturing procedure, and (for biological-origin drugs) the raw-material origin/animal-keeping-control specifications. | GMP Ordinance, Art. 7(1)-(5) | The Seihin Hyojun Sho document itself, quality-department-approved and cross-checked against the actual marketing approval on file | [REPRESENTATIVE] A Seihin Hyojun Sho that has not been updated to reflect a subsequent marketing-approval variation (e.g., a changed specification) is Japan's equivalent of the master-batch-record/specification-drift finding common in EU/US GMP audits — check the document's revision date against the most recent approval variation date. |
| 8 | Documented Procedures: the manufacturer must establish/maintain a sanitation-control standard code, a manufacturing-control standard code, and a quality-control standard code, plus documented procedures for: shipment control, validation, change control (Art. 14), deviation control (Art. 15), quality-information/defect handling, recall handling, self-inspection, training, and document/record control. All of the above must be placed at the manufacturing site. | GMP Ordinance, Art. 8(1)-(5) | The full documented-procedure set (SOP index) mapped one-to-one against this list; confirmation the current versions are physically/electronically available at the site (not only at head office) | [REPRESENTATIVE] A documented-procedure set missing one of the ten enumerated procedure types (most commonly: a standalone change-control or deviation-control SOP, as opposed to folding them informally into a general quality-manual) is a bright-line, easily-automatable completeness check. |
| 9 | Buildings and Facilities: cleaned/maintained/sterilised as needed with records; facilities for disposing poisonous gases where relevant; contamination-prevention buildings for work rooms (dust/microorganisms) unless equivalent-function facilities exist; restricted-passage buildings for weighing/formulating/filling/sealing rooms; dedicated, air-handling-segregated rooms for highly-sensitising or cross-contamination-risk products; adequate water-supply facilities. | GMP Ordinance, Art. 9(1)-(6) | Facility layout/floor plans mapped to each sub-requirement; sanitation records; dedicated-room documentation for high-hypersensitivity products (e.g., beta-lactams, hormones) | [REPRESENTATIVE] This is Japan's direct analogue to EU GMP Ch.5's cross-contamination-prevention requirement (§5.18-5.20) — the MHRA failure pattern of "no formal cross-contamination risk assessment, shared equipment not considered" documented in the companion EU rubric is the same failure mode Art. 9(5) is designed to prevent; score similarly. |
| 10 | Manufacturing Control: manufacturing department must, per documented procedure: establish/maintain documented manufacturing orders; manufacture per those orders; maintain lot-based manufacturing records; verify packaging/labelling correctness per lot with records; store products/materials properly with receipt/delivery records; verify facility cleaning with records; conduct personnel sanitation control with records; conduct periodic building/equipment maintenance and calibrate measuring equipment with records; verify manufacturing control is properly conducted and report in writing to the quality department. | GMP Ordinance, Art. 10(1)-(10) | Manufacturing-order documents; lot manufacturing records (batch records); packaging/labelling verification records; equipment calibration log; the written manufacturing-department-to-quality-department verification report itself | [REPRESENTATIVE] The written report from manufacturing department to quality department (Item 9) is a distinctive, checkable artifact — its absence, or its presence as a generic "no issues" boilerplate not tied to the specific lot's actual records, is a first-order document-analysis red flag, structurally similar to the EU GMP Annex 11 "blank tick-box, no real review" finding documented in the companion EU rubric. |
| 11 | Quality Control: quality department must, per documented procedure and as planned: collect/record samples per lot or controlled unit; conduct testing (in-house or outsourced, verified not to hinder proper testing) with records; store a reserve sample of at least twice the quantity needed for required testing, for shelf-life-plus-1-year (plus 1 month for radiopharmaceuticals) for products subject to GQP Ordinance market-release decisions; calibrate testing equipment with records; judge test results and report the judgement in writing to the manufacturing department. Where the exporting country's standards/verification procedures are deemed equivalent to Japan's, imported-product retesting may be replaced by verified foreign test records, subject to periodic verification duties. | GMP Ordinance, Art. 11(1)-(3) | Sample-collection records; test records/certificates of analysis; reserve-sample retention log with calculated retention-period end date; the written quality-department-to-manufacturing-department judgement report | [REPRESENTATIVE] Reserve samples retained for a calculated period that does not actually match the product's current approved shelf life (e.g., a shelf-life extension approved but the reserve-sample retention schedule not updated) is a direct structural parallel to the retention-trigger-drift finding flagged in the companion GLP rubric (21 CFR 58.195) — the same "retention keyed to an event that can shift after the fact" risk applies here. |
| 12 | Control of Shipment from Manufacturing Sites: quality department must evaluate manufacturing-and-quality-control results per documented procedure and decide whether to release product from the manufacturing site; personnel performing this duty must be competent and able to act without hindrance; the manufacturer must not ship product before this decision is properly made. | GMP Ordinance, Art. 12(1)-(4) | Batch-release decision record, quality-department-signed, dated before the recorded shipment date | [REPRESENTATIVE] A shipment record with a ship-date on or before the batch-release decision date is a bright-line, high-severity, automatable finding — structurally identical to the "batch released before QP certification" pattern that is a critical finding under both EU GMP (Authorised Person certification, Ch.1 principle vii) and 21 CFR 211. |
| 13 | Validation: designated personnel must conduct validation per documented procedure when (a) manufacturing of a drug newly starts at the site, (b) a change is made to the manufacturing procedure that seriously affects product quality, or (c) other cases where validation is deemed necessary; validation planning and results must be reported in writing to the quality department; where the validation results show improvement is needed, the manufacturer must take necessary action and record it. | GMP Ordinance, Art. 13(1)-(2) | Validation protocol/report package pre-dating first productive use (for new manufacturing) or pre-dating the change's implementation (for a quality-affecting change); the written report to the quality department | [REPRESENTATIVE] Retrospective validation — a "validation report" written after the process has already been running in production for the change it purports to validate — is explicitly the same failure mode flagged as unacceptable under EU GMP Annex 15's general principle in the companion EU rubric; Japan's Art. 13 wording ("newly start," implying before-the-fact) supports the same reading, though the Ordinance text does not use the word "prospective" as explicitly as Annex 15 does — flagged as an interpretive parallel, not an identical textual requirement. |
| 14 | Change Control: where any change to the manufacturing procedure could affect product quality, a designated person must, per documented procedure: evaluate quality effects and obtain quality-department approval before/based on that evaluation, with records; revise relevant documents, train personnel, and take other necessary actions once the change is approved. | GMP Ordinance, Art. 14(1)-(2) | Change-control record showing quality-department approval preceding implementation; associated document-revision and training records tied to the specific change | [REPRESENTATIVE] A change-control record where the quality-department approval date is on or after the date the change was actually implemented in production (a retroactive approval) is Japan's version of the "change controls raised after projects were initiated" finding documented as a repeated MHRA theme in the companion EU rubric — same check, same severity. |
| 15 | Deviation Control: where any deviation from the manufacturing procedure occurs, a designated person must, per documented procedure: record deviation details; and for serious deviations, evaluate quality effects and take necessary action, record the evaluation/action and report it in writing to the quality department, which must then verify the report — with that verification itself recorded and reported to the manufacturing manager. | GMP Ordinance, Art. 15(1)-(2) | Deviation log distinguishing minor vs. serious deviations; for serious deviations, the full chain: evaluation record → written report to quality department → quality-department verification record → report to manufacturing manager | [REPRESENTATIVE] Kobayashi Kako's documented pattern — manufacturing via undocumented/unauthorized procedure deviations sustained over many years without the Art. 15 evaluation-and-report chain ever being triggered — is the clearest real-world illustration of this clause's failure mode (see Sources; [REPRESENTATIVE], sourced via peer-reviewed literature, not a primary MHLW enforcement notice). A document-analysis check should flag any manufacturing record implying a deviation from the documented manufacturing order with no corresponding Art. 15 deviation record. |
| 16 | Handling of Quality Information and Quality Defects: on receiving quality information about a product (unless obviously unrelated to the manufacturing site), a designated person must investigate the cause and take corrective action where needed, record details/investigation/improvements, and promptly report in writing to the quality department, which must verify the report; where a quality defect (or its possibility) is identified, the quality department must report this in writing to the manufacturing manager. | GMP Ordinance, Art. 16(1)-(2) | Quality-information/complaint log with investigation records; quality-department verification record; escalation-to-manufacturing-manager record where a defect is confirmed or suspected | [REPRESENTATIVE] This is Japan's direct analogue to EU GMP Ch.1 root-cause-analysis/CAPA requirements and to the EU GDP Ch.6 complaints-handling chapter in the companion rubric — the same "complaint logged but investigation superficial or absent" failure mode applies. |
| 17 | Handling of Recall: where a product recall is conducted due to quality issues (unless obviously unrelated to the manufacturing site), a designated person must segregate recalled product, dispose of it appropriately after a storage period, and record/report recall-handling details in writing to the quality department and manufacturing manager. | GMP Ordinance, Art. 17(1)-(2) | Recall-handling record with segregation/storage/disposal evidence; the written report to quality department and manufacturing manager | [REPRESENTATIVE] Structurally parallel to EU GDP Ch.6's recall-effectiveness requirements in the companion EU rubric, though Japan's Art. 17 (manufacturing-site level) is narrower in scope than the GDP chapter (distribution-level) — do not conflate the two when cross-referencing. |
| 18 | Self-Inspections: a designated person must periodically self-inspect manufacturing-and-quality-control at the site per documented procedure, report results in writing to the manufacturing manager, and record results; the manufacturer must take necessary corrective action based on self-inspection findings and record that action. | GMP Ordinance, Art. 18(1)-(2) | Self-inspection schedule and reports; corrective-action records tied to specific self-inspection findings, with evidence of closure | [REPRESENTATIVE] A self-inspection programme that exists on paper (a schedule) but shows no completed reports for the current period, or shows findings with no tracked corrective action, is the same "self-inspection theatre" finding format documented in the EU GDP rubric's "RPs had failed to conduct a self-inspection since appointment" MHRA example. |
| 19 | Training: a designated person must implement planned training necessary for manufacturing-and-quality-control personnel, report training progress in writing to the manufacturing manager, and record training implementation. | GMP Ordinance, Art. 19(1)-(3) | Training plan/schedule; completion records tied to named individuals and specific competencies; progress reports to the manufacturing manager | [REPRESENTATIVE] Training records that show course completion but are not mapped to the specific role/duty the individual actually performs (e.g., a generic "GMP awareness" record standing in for role-specific qualification) is a common, low-severity but frequently-cited gap across all GMP frameworks. |
| 20 | Control of Documents and Records: for all documents/records specified in this Ordinance, a designated person must, per documented procedure: approve/distribute/maintain documents on establishment or revision; date-stamp establishment/revision and maintain revision-history records; and retain documents/records for 5 years (or 1 year past shelf life if shelf-life-plus-1-year exceeds 5 years) from establishment date (or, for records, from the date they fell into disuse). | GMP Ordinance, Art. 20(1)-(3) | Document-control register with revision-history log; retention schedule keyed correctly to the 5-year-or-shelf-life-plus-1-year rule, whichever is longer | [REPRESENTATIVE] This is the general retention baseline that Sections 2-4 below (APIs, sterile drugs, biological-origin drugs) each separately extend — a document-analysis tool should not apply the flat 5-year/shelf-life rule to API, sterile, or biological-origin product records without first checking whether the longer, product-category-specific retention period (Arts. 22, 30) applies instead. This layering (general rule + product-category overrides) is structurally distinctive relative to both EU GMP's flatter Ch.4 retention rule and 21 CFR 211.180's simpler post-expiration/distribution rule — flag as a Japan-specific scoring node, not a reused EU/US retention check. |
CHAPTER 2, Section 2 — Manufacturing Control and Quality Control of APIs
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 21 | Reserve samples for APIs: notwithstanding the general Art. 11(1)(3) reserve-sample rule, API manufacturers must store a reserve sample of at least twice the required testing quantity, per lot, for 3 years from shipment completion (for products with an assigned retest date) or 1 year past shelf life (for other API products). | GMP Ordinance, Art. 21(1)-(2) | API reserve-sample retention log distinguishing retest-date products (3-year-from-shipment rule) from shelf-life products (1-year-past-shelf-life rule) | [REPRESENTATIVE] APIs with an assigned retest date are the more common case for most active substances — a reserve-sample schedule that defaults to the shelf-life rule for a retest-date product will retain samples for the wrong period (usually too short, since retest-date products often ship years before final use) — a distinctive, checkable Japan-specific API gap. |
| 22 | Document/record retention for APIs: notwithstanding the general Art. 20(3) 5-year rule, API manufacturing/quality records must be retained for 1 year past shelf life from establishment/disuse date, or 3 years from lot-shipment-completion for retest-date products. | GMP Ordinance, Art. 22 | API-specific retention schedule, distinguished from the general Art. 20 rule | [REPRESENTATIVE] Same underlying risk as row 21 — API records retained under the general Art. 20 rule rather than the longer Art. 22 rule is a plausible under-retention gap. |
CHAPTER 2, Section 3 — Manufacturing Control and Quality Control of Sterile Drugs
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 23 | Buildings and facilities for sterile drugs: in addition to Art. 9, sterile-drug manufacturing sites need cleanliness-graded work rooms/controlled work areas appropriate to product type/dosage form/process; dedicated drying/sterilising rooms for cleaned containers; sterilisation apparatus appropriate to the product; filtered clean air with controlled pressure differentials for aseptic operations; and easily-cleanable/sterilisable liquid-contacting piping for injectable-drug manufacturing. | GMP Ordinance, Art. 23(1)-(5) | Facility qualification/cleanliness-classification documentation; HVAC pressure-differential monitoring records; piping cleaning/sterilisation validation records | [REPRESENTATIVE] This is Japan's direct analogue to the fully-rewritten EU GMP Annex 1:2023 (Contamination Control Strategy) already modeled in this project's separate eu-annex1-rubric.md — a document-analysis pass on a Japan sterile-drug site should cross-reference both rubrics, since a CCS-style gap analysis under Annex 1 substantively covers most of what Art. 23 requires, even though the citations differ. |
| 24 | Manufacturing control for sterile drugs: in addition to Art. 10, manufacturing department must appropriately establish/control degree of environmental cleanliness control per product/process; control values for microorganism counts/contamination-prevention actions; process-control values essential to sterility assurance; water-quality control values; and personnel sanitation control (restricted work-area access, strict procedures for animal-tissue/microorganism-handling personnel, gowning discipline, health declaration for potentially contaminating conditions). | GMP Ordinance, Art. 24(1)-(7) | Environmental monitoring (viable/non-viable particle count) records; water system monitoring records; gowning-qualification records; personnel health-declaration records | [REPRESENTATIVE] Environmental monitoring data that is collected but not actually reviewed/trended against action limits before batch release is the sterile-manufacturing equivalent of the EU GMP Ch.6 "electronic data ticked but not reviewed" finding documented in the companion EU rubric. |
| 25 | Training for sterile-drug personnel: in addition to Art. 19, personnel engaged in sterile-drug manufacturing/testing must receive training in sanitation control and microbiology; personnel in clean/aseptic areas must receive training on contamination-prevention actions. | GMP Ordinance, Art. 25(1)-(2) | Sterile-manufacturing-specific training records (microbiology, aseptic technique), distinct from general Art. 19 training records | [REPRESENTATIVE] Aseptic-technique training that is a one-time onboarding event with no periodic requalification (e.g., no repeat media-fill-linked competency check) is a common gap flagged in sterile-manufacturing audits generally. |
CHAPTER 2, Section 4 — Manufacturing Control and Quality Control of Biological-origin Drugs, etc.
(Includes biological preparations, gene-recombination-technology drugs, cell/tissue-culture-technology drugs, and cell/tissue-based drugs. This section is dense — 5 articles, Arts. 26-30 — covering facility segregation for microorganism/animal-handling operations, donor/donor-animal screening and traceability, strain-handling records, and materially longer retention periods. Summarized at moderate granularity below; a biologics-focused document-analysis pass should read the full article text, not rely solely on this summary.)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 26 | Buildings and facilities for biological-origin drugs: dedicated, segregated facilities for microorganism storage/cultivation/inactivation, animal-handling/inoculation, undiluted-solution dilution/subdivision, and (for cell/tissue-based drugs by extension) equivalent segregation for donor material — with aseptic-room/anteroom requirements for specified sub-processes. | GMP Ordinance, Art. 26(1)-(3) | Facility segregation floor plans mapped to each listed function; aseptic-room/anteroom access-control documentation | [REPRESENTATIVE] Shared equipment/rooms across different microorganism strains or cell/tissue donor sources without documented segregation is the biological-origin-drug equivalent of the cross-contamination-risk-assessment gap flagged under Art. 9/EU GMP Ch.5 above — same underlying principle, higher consequence given biological cross-contamination risk. |
| 27 | Manufacturing control for biological-origin drugs: inactivation/elimination verification for products requiring it; continuous process-parameter measurement for fermentation-based processes; column-chromatography contamination-prevention and endotoxin measurement; incubation-tank condition control; personnel sanitation control including 6-monthly medical checkups for clean/aseptic-area personnel; animal health verification before use; strain-handling records (name, container ID, receipt date/source, biological properties, passage status); labelling/restriction controls for equipment used with high-risk pathogens (smallpox, poliovirus, spore-formers, tubercle bacilli); biological-origin raw-material verification against Seihin Hyojun Sho; origin-traceability information maintenance (directly or via contracted "biological-origin raw material origin collectors"). | GMP Ordinance, Art. 27(1)-(13) | Process-parameter continuous-monitoring records; strain log; personnel medical-checkup records (≤6-month interval); raw-material-origin verification records; origin-collector contracts where traceability is outsourced | [REPRESENTATIVE] Strain-handling records (Item 9) with gaps in passage-status documentation are a distinctive, checkable biologics-specific gap with no direct analogue in the small-molecule-drug rows above — flag as its own scoring node rather than folding into general record-control checks. |
| 28 | Quality control for biological-origin and cell/tissue-based drugs: notwithstanding the general Art. 11(1)(3) and Art. 21 reserve-sample rules, reserve samples (or, where contractually delegated to an origin-collector, the underlying raw materials) must be retained for 10 years plus shelf life (specified biological-origin drugs) or an "appropriate period" (cell/tissue-based drugs); additional sample-identification, in-process testing, animal-testing, and strain-record duties apply; cell/tissue-based drugs additionally require donor/donor-animal testing before and after receipt with detailed screening-record requirements (collection premises, date, donor-screening questionnaire/testing results, collection-process records). | GMP Ordinance, Art. 28(1)-(4) | 10-year-plus-shelf-life reserve-sample retention log for specified biological-origin drugs; donor-screening records including premises/date/questioning-and-testing results for cell/tissue-based drugs | [REPRESENTATIVE] The 10-year-plus-shelf-life reserve-sample rule is dramatically longer than the general Art. 11 rule (shelf-life-plus-1-year) — a document-analysis tool defaulting to the general rule for a biological-origin product would understate the required retention period by potentially a decade; this is the single most consequential retention-period distinction in the entire Ordinance. |
| 29 | Training for biological-origin-drug personnel: in addition to Arts. 19 and 25, personnel must receive training in microbiology, medicine, veterinary medicine, etc.; personnel in aseptic areas or pathogenic-microorganism-handling areas must receive contamination-prevention training. | GMP Ordinance, Art. 29(1)-(2) | Biologics-specific training records (microbiology/veterinary medicine content), distinct from Art. 19/25 general and sterile-drug training | [REPRESENTATIVE] |
| 30 | Document/record retention for biological-origin and cell/tissue-based drugs: notwithstanding Art. 20(3), retention periods are 30 years plus shelf life (specified biological-origin drugs, or those manufactured using human blood), 10 years plus shelf life (other biological-origin/cell-tissue-based drugs), or the general 5-year rule for non-biological-origin products under this section — training records always retained 5 years regardless. | GMP Ordinance, Art. 30(1)-(3) | Retention schedule correctly distinguishing the three tiers (30-year, 10-year, 5-year) by product category | [REPRESENTATIVE] The 30-year-plus-shelf-life tier (human-blood-derived and specified biological-origin products) is the longest retention period anywhere in the Ordinance — a document-analysis tool built primarily against small-molecule-drug retention expectations (5 years, or the API 1-year/3-year rules) will badly under-flag retention risk for a plasma-derived or specified-biological product if it does not specifically detect the product category first. |
CHAPTER 2, Section 5 — Miscellaneous Provision
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 31 | Exceptions to record retention: for biological-origin drugs designated by the Minister of Health, Labour and Welfare, the retention period specified by the Minister applies instead of Art. 30, unless the records are maintained for the required period by a contracted biological-origin raw-material origin collector. | GMP Ordinance, Art. 31 | Minister-designated retention period documentation (where applicable) or origin-collector contract assigning retention responsibility | [REPRESENTATIVE] A gap here (no traceable Minister-designation lookup, no origin-collector contract) leaves the applicable retention period undefined — treat as an open question requiring manual regulatory lookup rather than a default assumption. |
CHAPTER 3 — Manufacturing Control and Quality Control in Manufacturing Sites of Quasi-drug Manufacturers, etc.
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 32 | Quasi-drugs: Chapter 2 (excluding a handful of named carve-outs — Art. 7 Item 4, Art. 9 Item 5(d), and Section 4 in full) applies mutatis mutandis to quasi-drug manufacturers, with defined term-substitutions (e.g., "manufacturing manager" reads as "responsible engineering manager," "sterile drugs" in Section 2 reads as "sterile quasi-drugs"). | GMP Ordinance, Art. 32 | Same evidence types as the Chapter 2 rows above, applied to the quasi-drug product and with the Art. 32 term-substitutions in mind | [REPRESENTATIVE] The most common quasi-drug-specific scoring error is applying a Chapter 2 row without the Art. 32 substitutions — e.g., checking for a "manufacturing manager" designation when the correct Japanese-law role for a quasi-drug site is the "responsible engineering manager." Regscribe's rubric-matching logic should branch on product type (drug vs. quasi-drug) before applying Chapter 2 rows, not apply them identically. |
Supplementary Provisions
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| — | Enforcement date: 1 April 2005. Transitional measures: certain buildings/facilities articles (Arts. 9, 23, 26, and their quasi-drug equivalents) did not apply to foreign manufacturers for 2 years from enforcement; the prior 1999 import/distribution ordinance (No. 62) expired 31 March 2005. | Supplementary Provisions, Arts. 1-3 | N/A — historical/transitional reference only, not relevant to current-day scoring | N/A |
Cross-reference: Japan GMP Ordinance vs. EU GMP (Vol. 4) vs. 21 CFR 210/211
| Japan GMP Ordinance concept | Nearest EU GMP Vol. 4 analogue | Nearest 21 CFR 210/211 analogue | Notes |
|---|---|---|---|
| Quality department independence from manufacturing department (Art. 4(2)) | Ch.1 Pharmaceutical Quality System / Authorised Person independence | §211.22(a) QCU independence | Same underlying principle across all three frameworks — check actual reporting line, not org-chart label, in all cases. |
| Seihin Hyojun Sho / Product Standard Book (Art. 7) | Product Specification File concept (implicit across Ch.4/Annex 15) | Master production/control records (§211.186) | Japan's is a single named, quality-department-approved document type — arguably more explicitly unified than the EU/US equivalents, which are spread across several document types. |
| Change Control (Art. 14) | Ch.1 §1.4(xii)-(xiii) | §211.100(b) (implicit in written-procedure requirements) | Same "approval must precede implementation" principle; Japan's Art. 14 text is less granular than EU GMP's explicit pre-/post-implementation-evaluation language — treat as substantively equivalent, not textually identical. |
| Deviation Control (Art. 15) | Ch.1 §1.4(xiv) root-cause/CAPA | §211.100(b), §211.192 | Japan explicitly tiers "serious" vs. non-serious deviations for escalation purposes — a distinction not as explicitly drawn in EU GMP Ch.1 or Part 211 text. |
| Validation (Art. 13) | Annex 15 (Qualification and Validation) | §211.100(a), §211.110 | EU Annex 15 explicitly states retrospective validation is unacceptable; Japan's Art. 13 implies prospective validation via "newly start"/"before... change" wording but does not use the word "prospective" as explicitly. |
| Reserve samples (Arts. 11, 21, 28) | Ch.1 §1.3(viii) reference/reserve samples | §211.170 reserve samples | Japan's retention periods are product-category-tiered and often longer than the EU/US flat rules — notably the 10-year/30-year-plus-shelf-life tiers for biological-origin drugs (Art. 28/30), which have no direct EU/US flat-rule equivalent of the same length. |
| Document/record retention (Art. 20 general; Arts. 22, 30 category-specific overrides) | Ch.4 retention (5 years commonly cited; EU GDP: ≥5 years) | §211.180(a) (1 yr past expiration / 3 yrs past distribution) | Japan's layered general-rule-plus-category-override structure (5 yr / API-specific / biological-origin-specific) is structurally closer to the GLP rubric's "retention keyed to an event" complexity than to the EU/US GMP rubrics' flatter rules — do not reuse the EU/US retention-scoring node as-is. |
| GMP Ordinance + GQP Ordinance + GVP Ordinance (three separate ordinances) | Single EU GMP Vol. 4 framework covers manufacturing; EU pharmacovigilance legislation (GVP) is separate EU law | Part 211 (manufacturing) + Part 314/postmarketing safety reporting reasonably separate in US law too | Japan's three-way split is procedurally more explicit than the EU's (which functionally separates GMP from pharmacovigilance law but doesn't brand a parallel "GQP" concept) — flag this as the most important structural difference for Regscribe's rubric-selection UI: a Japan-market customer needs GMP and GQP compliance evidence, and this rubric only covers the former. |
Recommendation: extend this project's shared "Evidence Type" layer (already proposed in gmp-gdp-rubric.md and cfr58-glp-rubric.md) with Japan-specific tags — seihin_hyojun_sho, manufacturing_quality_dept_org_chart, biological_origin_reserve_sample_log — rather than building a fourth parallel evidence taxonomy. Most rows above (change control, deviation control, validation, batch release, self-inspection, training, CAPA/quality-information-handling) map cleanly onto evidence types already defined for the EU/US rubrics; only the reserve-sample/retention-tiering and Seihin Hyojun Sho concepts are genuinely Japan-specific new evidence types.
Gaps / follow-ups before this goes into production scoring
- Amendment currency is the single biggest gap in this document. The primary-source PDF read this session (
pmda.go.jp/files/000153399.pdf) carries no visible revision-date stamp and is labeled only "Tentative translation VER. 1." Secondary WebSearch results referenced a possible 28 April 2021 partial amendment and a claim about added provisions for remanufactured single-use devices — neither was independently verified against a primary document this session, and the single-use-device claim looks more consistent with Japan's separate medical-device QMS ordinance than with this drug/quasi-drug GMP ordinance. Recommend a dedicated follow-up session that (a) checks PMDA's English "Ministerial Ordinances" index page (pmda.go.jp/english/review-services/regulatory-info/0001.html) for a newer-dated translation of Ordinance No. 179, and (b) searches MHLW's Japanese-language ordinance database directly for amendment history, before treating the article numbering/text above as current-as-of-2026. - No primary MHLW/PMDA enforcement-notice document was found for either the Kobayashi Kako or Nichi-Iko cases — both are sourced from a peer-reviewed journal article (PMC10230667) cross-checked against trade press, not from an MHLW administrative-disposition notice or Fukui Prefecture's own published order. The specific GMP Ordinance article(s) formally cited in the actual suspension orders were not confirmed. Recommend a follow-up WebSearch targeting Fukui Prefecture's or MHLW's own published disposition notices (likely Japanese-language only) if article-level precision on these two cases is needed for production scoring.
- No MHLW/PMDA-published aggregate GMP inspection-deficiency dataset (English-language) was found, unlike the MHRA deficiency-trend data that grounds the companion
gmp-gdp-rubric.md. Every failure-pattern cell in this document is therefore either a named enforcement case or a structural/interpretive inference from the Ordinance's own text and its EU/US analogues — no clause in this document should be treated as empirically frequency-weighted the way several EU GMP rows are. If Regscribe wants severity-weighting for Japan GMP findings, treat Arts. 4 (dept. independence), 12 (batch release), 14/15 (change/deviation control), and 28/30 (biological-origin retention) as reasoned high-consequence defaults based on structural-uniqueness and the Kobayashi Kako/Nichi-Iko fact patterns — not as citation-frequency-derived weights. - GQP Ordinance (No. 136, 2004) and GVP Ordinance (No. 135, 2004) are explicitly out of scope for this document and have not been separately researched to rubric-depth. A Japan-market pharma/biotech customer's audit-readiness posture is incomplete without both — recommend these as candidate future rubrics, not folded into this one (per this project's one-framework-per-real-need pattern).
- The GMP Ordinance's own English translation is explicitly "tentative... not authentic and not formally authorised" per PMDA's own footnote. Any article text quoted/paraphrased above should be understood as reflecting that non-authoritative English rendering — the Japanese original governs in any conflict, per PMDA's own stated caveat (mirrored from the PIC/S-notification PDF's identical disclaimer, which used the same boilerplate).
- Chapter 2 Section 4 (biological-origin drugs, Arts. 26-30) was summarized at moderate rather than exhaustive granularity given its density (5 articles covering facility segregation, strain records, donor screening, and three separate retention tiers) — a biologics-focused production pass should re-read the full article text from the primary PDF (pages 15-22 of the fetched source) rather than relying solely on the summarized rows above.
- The Kobayashi Pharmaceutical beni-koji (2024) case was deliberately excluded, not overlooked — it is a food-labeling matter outside this Ordinance's scope, and including it would have been exactly the kind of conflation this project's sourcing rules are designed to prevent. Flagged here so a future session doesn't second-guess the omission without re-reading this reasoning.